Vol. 6 No. 6 (2026): June
Reimbursement Reviews

Durvalumab (Imfinzi)

decorative image of the issue cover

Published June 26, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses durvalumab (Imfinzi), 120 mg/2.4 mL and 500 mg/10 mL single-use vials for IV infusion.
  • Indication: In combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, for the treatment of patients with resectable Stage II, IIIA, or IIIB (T3-4 N2) non–small cell lung cancer and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.